ILOPROST TROMETHAMINE: 71 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
71
Total FAERS Reports
14 (19.7%)
Deaths Reported
33
Hospitalizations
71
As Primary/Secondary Suspect
10
Life-Threatening
First Report: 2007 · Latest Report: 20250526
What Are the Most Common ILOPROST TROMETHAMINE Side Effects?
#1 Most Reported
Right ventricular failure
11 reports (15.5%)
#2 Most Reported
Off label use
11 reports (15.5%)
#3 Most Reported
Encephalopathy
8 reports (11.3%)
All ILOPROST TROMETHAMINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 11 | 15.5% | 2 | 4 |
| Right ventricular failure | 11 | 15.5% | 10 | 6 |
| Encephalopathy | 8 | 11.3% | 0 | 8 |
| Congestive cardiomyopathy | 7 | 9.9% | 0 | 0 |
| Disease progression | 7 | 9.9% | 6 | 6 |
| Sepsis | 7 | 9.9% | 6 | 6 |
| Drug ineffective | 6 | 8.5% | 5 | 0 |
| Pneumonia | 6 | 8.5% | 5 | 6 |
| Cardiac dysfunction | 5 | 7.0% | 5 | 5 |
| Galectin-3 increased | 5 | 7.0% | 5 | 5 |
| Left ventricular dysfunction | 5 | 7.0% | 5 | 5 |
| Multiple organ dysfunction syndrome | 5 | 7.0% | 5 | 5 |
| Myocardial fibrosis | 5 | 7.0% | 5 | 5 |
| Myocarditis | 5 | 7.0% | 5 | 5 |
| Respiratory failure | 5 | 7.0% | 5 | 5 |
| Right ventricular dilatation | 5 | 7.0% | 5 | 5 |
| Systemic scleroderma | 5 | 7.0% | 5 | 5 |
| Ventricular hypokinesia | 5 | 7.0% | 5 | 5 |
Who Reports ILOPROST TROMETHAMINE Side Effects? Age & Gender Data
Gender: 70.6% female, 29.4% male. Average age: 48.4 years. Most reports from: FR. View detailed demographics →
Is ILOPROST TROMETHAMINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2007 | 3 | 3 | 0 |
| 2014 | 6 | 2 | 1 |
| 2017 | 2 | 0 | 0 |
| 2018 | 4 | 0 | 4 |
| 2019 | 8 | 0 | 5 |
| 2021 | 5 | 0 | 3 |
| 2022 | 2 | 1 | 2 |
| 2023 | 8 | 0 | 8 |
| 2024 | 3 | 0 | 2 |
| 2025 | 2 | 0 | 0 |
What Is ILOPROST TROMETHAMINE Used For?
| Indication | Reports |
|---|---|
| Pulmonary arterial hypertension | 12 |
| Peripheral arterial occlusive disease | 8 |
| Peripheral ischaemia | 8 |
| Systemic scleroderma | 8 |
| Osteonecrosis | 7 |
| Raynaud's phenomenon | 5 |
Official FDA Label for ILOPROST TROMETHAMINE
Official prescribing information from the FDA-approved drug label.